scispace - formally typeset
Search or ask a question
Institution

Central Drug Research Institute

FacilityLucknow, Uttar Pradesh, India
About: Central Drug Research Institute is a facility organization based out in Lucknow, Uttar Pradesh, India. It is known for research contribution in the topics: Leishmania donovani & Brugia malayi. The organization has 4357 authors who have published 7257 publications receiving 143871 citations. The organization is also known as: Central Drug Research Institute, Lucknow & CDRI.


Papers
More filters
Journal ArticleDOI
TL;DR: The synthesis of a series of benzocoumarin keto-enamine schiff bases is reported, which significantly lowered the plasma triglyceride levels, total cholesterol and total cholesterol levels, and accompanied by an increase in HDL-C/TC ratio in hyperlipidemic hamsters to a greater degree than the reference drugs atorvastatin and lovastatin.

51 citations

Journal ArticleDOI
TL;DR: It is shown that whilst SPINK1 is transcriptionally repressed by androgen receptor and its co-repressor REST, it is upregulated after androgen-deprivation therapy, which leads to neuroendocrine differentiation of prostate cancer cells.
Abstract: Emergence of an aggressive androgen receptor (AR)-independent neuroendocrine prostate cancer (NEPC) after androgen-deprivation therapy (ADT) is well-known. Nevertheless, the majority of advanced-stage prostate cancer patients, including those with SPINK1-positive subtype, are treated with AR-antagonists. Here, we show AR and its corepressor, REST, function as transcriptional-repressors of SPINK1, and AR-antagonists alleviate this repression leading to SPINK1 upregulation. Increased SOX2 expression during NE-transdifferentiation transactivates SPINK1, a critical-player for maintenance of NE-phenotype. SPINK1 elicits epithelial-mesenchymal-transition, stemness and cellular-plasticity. Conversely, pharmacological Casein Kinase-1 inhibition stabilizes REST, which in cooperation with AR causes SPINK1 transcriptional-repression and impedes SPINK1-mediated oncogenesis. Elevated levels of SPINK1 and NEPC markers are observed in the tumors of AR-antagonists treated mice, and in a subset of NEPC patients, implicating a plausible role of SPINK1 in treatment-related NEPC. Collectively, our findings provide an explanation for the paradoxical clinical-outcomes after ADT, possibly due to SPINK1 upregulation, and offers a strategy for adjuvant therapies.

51 citations

Journal ArticleDOI
TL;DR: It is suggested that CC-treatment at higher doses specifically induces cellular apoptosis and inhibits cellular proliferation; whereas at lower doses, it inhibits cellular migration and invasion.

51 citations

Journal ArticleDOI
TL;DR: In this paper, the reaction of aldehydes with 2−aminophenol and O−phenylenediamines in the presence of iodine was used to synthesize 2−Arylbenzoxazoles and 2−arylbenzimidazoles.

51 citations

Journal ArticleDOI
TL;DR: It may be suggested that impairment of neuromuscular coordination is inked to oxidative stress rather than mitochondrial enzyme deficiency, all the processes are correlated with each other with the progression of time.

51 citations


Authors

Showing all 4385 results

NameH-indexPapersCitations
Sanjay Kumar120205282620
John A. Katzenellenbogen9569136132
Brajesh K. Singh8340124101
Gaurav Sharma82124431482
Sudhir Kumar82524216349
Pramod K. Srivastava7939027330
Mohan K. Raizada7547321452
Syed F. Ali7144618669
Ravi Shankar6667219326
Ramesh Chandra6662016293
Manoj Kumar6540816838
Manish Kumar61142521762
Anil Kumar Saxena5831010107
Sanjay Krishna5662413731
Naibedya Chattopadhyay562429795
Network Information
Related Institutions (5)
Merck & Co.
48K papers, 1.9M citations

93% related

GlaxoSmithKline
21.1K papers, 1.1M citations

92% related

Bristol-Myers Squibb
21K papers, 932.5K citations

92% related

Novartis
50.5K papers, 1.9M citations

91% related

Pfizer
37.4K papers, 1.6M citations

91% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
20233
202255
2021306
2020232
2019246
2018289